Skip to Content
Exit Menu

Research area(s)

Dr Karteris has a long standing interest in mTOR signalling with emphasis in reproductive endocrinology and ovarian cancer. His lab is also active in the field of biomarker development using liquid biopsies. Dr Karteris has a recognized publication record in receptor biochemistry and cell signalling. He has published 64 research manuscripts, presented over 100 research abstracts in leading national and international conferences.  Many of these papers are generating a strong and influential impact not only to the biomedical field (as it is evident from the high citation index; 25) but also to the society as they deal with topical issues such as effects of stress during pregnancy. Moreover Dr Karteris has established collaborations with leading authorities in their fields and has been successful in obtaining research grants at national and international level.

Research Interests

  • Role of endocrine disrupting chemicals in the feto-placental unit
  • Detection and characterisation of circulating tumour cells
  • Use of liquid biopsies as cancer biomargers of diagnostic and prognostic value
  • Development of fetal-placental 3D cultures as a screening platform for EDCs

Research supervision

With regards to postgraduate supervision, I have so far successfully supervised 5 PhD students and currently supervising (as first supervisor) another 3, and I act as a second supervisor for another PhD student.

Research project(s) and grant(s)

(since joined Brunel)

  • Isamambard PhD Scholarship (2018-2021): Investigate the effects of BPA in ovarian  cancer (£66,000).
  • NHS Mt Vernon Cancer Centre; RA post (2017-2019): Detection and enumeration of rare circulating tumour cells (£80,000).
  • Catalyst Fund; Pilot Project – Brunel University (co-applicant): The multifactorial aetiology of breast cancer – establishing new tools to investigate the role of chemicals and lifestyle factors on breast cancer development (£15,000).
  • Isamambard PhD Scholarship (2015-2018): Investigate the effects of endocrine disrupting chemicals in the human placenta (£66,000).
  • Clinical Trials Research Trust; PhD Scholarship (2014-2017): Development of a prognostic test for ovarian cancer (£60,000).
  • Friedreich’s Ataxia Research Alliance (2013-2014): “Investigation of diazoxide as a novel frataxin-increasing therapy for Friedreich ataxia”. Co-PI ($45,000).
  • National Institutes of Health (NIH) USA (2006-2012): “Characteristics of a putative steroid membrane receptor”. Co-applicant to Prof. P. Thomas, University of Texas, USA. ($1.6 million).
  • PhD studentship (BJS Biotechnology, 2011-2014): “mTOR signalling in ovarian cancer” (£150,000).
  • Royal Society: Laboratory Visit award (£2,400 January 2011).
  • Society for Endocrinology (2007-2008), UK: Small grant programme (£9,700).
  • Young Investigator Award (2006), European Federation of Endocrine Societies (€ 2,000)